OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

Cancers & treatments·Sequencing

Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersFRα
Early / localised1·
Advanced, first line1·
Third line and beyond·1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersEarly stage (patches and plaques)Topical steroids, nitrogen mustard or bexarotene gel; narrowband UVB or PUVA phototherapy; local radiotherapy; total skin electron beam therapy for widespread disease.
Total skin electron beam therapySuperficial and orthovoltage radiotherapy for skin cancerBexarotene
43

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced skin or blood diseaseExtracorporeal photopheresis, interferon, oral bexarotene, low-dose methotrexate; mogamulizumab for blood involvement (MAVORIC); brentuximab vedotin for CD30-positive disease (ALCANZA); vorinostat or romidepsin.
Methoxsalen (extracorporeal photopheresis)BexaroteneMethotrexateMogamulizumabBrentuximab vedotinVorinostatRomidepsin
83

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
FRαRefractory or transformedGemcitabine or liposomal doxorubicin chemotherapy; allogeneic stem cell transplant in fit younger patients.
GemcitabineAllogeneic stem cell transplantation
92

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.